Ventus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read more
Pfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read more
Machine learning tissue classifiers are one of the most powerful and promising AI-based clinical research solutions for all types of
Read more
American clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read more
Lutathera®, developed by Swiss drugmaker Novartis has demonstrated a substantial 72% reduction in the risk of disease progression or death
Read more
AbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read more
Moderna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read more
The MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read more
Coya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read more
ReCode Therapeutics, announced the dosing of the first participants in a Phase 1 trial designed to evaluate the safety and
Read more